Global Duchenne Muscular Dystrophy Market

Global Duchenne Muscular Dystrophy Market Size, Share, Growth Analysis, By Therapy(Mutation Suppression, Exon Skipping Approach), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies) - Industry Forecast 2022-2028


Report ID: SQSG35I2036 | Region: Global | Published Date: September, 2022 | Pages: 157 | Tables: 63 | Figures: 65

Global Duchenne Muscular Dystrophy Market Insights

Global duchenne muscular dystrophy market was valued at USD 693.34 million in 2021, and it is expected to reach a value of USD 1533.72 million by 2028, at a CAGR of more than 11.87% over the forecast period (2022–2028).

Duchenne muscular dystrophy is an illness in which muscular weakness happens. Muscle weakness is a defining feature of this hereditary condition. This rare illness primarily affects males. This illness results in mental retardation, respiratory failure, pneumonia, heart failure, muscle weakness, and intellectual incapacity. With the help of this diagnostic care, people with Duchenne muscular dystrophy can receive precise and effective treatment. This sort of diagnostic therapy lessens or manages symptoms but does not provide a cure. In addition to stem cell therapy and gene therapy, medications like steroids are used to treat Duchenne muscular dystrophy and lessen its symptoms.

In the case of DMD, a characteristic of this inherited illness is muscle weakness. Males are the main victims of this rare disease. Mental retardation, pneumonia, heart failure, respiratory failure, muscle weakness, and intellectual disability are all side effects of this condition. People with Duchenne muscular dystrophy can get precise and efficient treatment with the use of this diagnostic care. While not offering a cure, this type of diagnostic therapy lowers or manages symptoms. Drugs like steroids are used to treat Duchenne muscular dystrophy and decrease its symptoms in addition to stem cell therapy and gene therapy.

Global duchenne muscular dystrophy market is anticipated to rise as R&D spending increases to create possible treatments for DMD. For instance, the Muscular Dystrophy Association (MDA), United States, funded $75,000 in research and development to create a DMD treatment. More than 150 hospitals, healthcare facilities, and care facilities in the United States and other nations have received grants from the group.

Additionally, factors like ongoing research into gene and stem cell therapy and exon skipping drugs for DMD treatment are projected to drive global duchenne muscular dystrophy market.

To get more reports on the above market click here to Buy The Report

Global Duchenne Muscular Dystrophy Market Segmental Analysis

Global duchenne muscular dystrophy market is segmented based on distribution channel, therapy, and region. On the basis of therapy, the market is segmented into mutation suppression, exon skipping approach, others therapies. On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Based on region it is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.

Analysis by Therapy

On the basis of therapy, the market is segmented into mutation suppression, exon skipping approach, others therapies. Among these the segment of Exon Skipping Approach held the largest share as the segment has grown due to result of EXONDYS 51 becoming more widely used. Exon 51 can be skipped to treat individuals with a proven hereditary mutation in the dystrophin gene, making EXONDYS 51 the first Duchenne muscular dystrophy medication that the FDA has approved. In some patients, it aids in the body's production of a cut-down form of the dystrophin protein. The dystrophin gene, which encodes a protein crucial for preserving the integrity of the membrane of muscle cells, is primarily responsible for Duchenne muscular dystrophy. To allow the remaining exons to come together, one prospective therapeutic strategy is to mask an exon near to the location where the others are missing. Exon-skipping therapy is one of the most effective methods for restoring the expression of a shorter but functional dystrophin protein.

Analysis by Distribution Channel

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment to grow at faster rate. The Duchenne muscular dystrophy market includes the introduction of novel medications and treatments, substantial funding from numerous companies for drug development, disease-modifying treatments, and assistance from patient advocacy groups for the regulatory approval procedure. The expansion of the global market is projected to be fueled by an increase in the number of clinical trials exploring potential treatments for Duchenne muscular dystrophy and a robust product pipeline. Duchenne muscular dystrophy treatment is predicted to advance with the development of mutation-specific medicines. Duchenne muscular dystrophy's rising disease burden, rising pharmaceutical research and development expenditures to produce innovative disease therapies, and rising DMD awareness campaigns all contribute to the market's expansion.

To get detailed analysis on other segments, Request For Sample Report

Global Duchenne Muscular Dystrophy Market Regional Insights

North America dominated the global duchenne muscular dystrophy market. The market in North America is expected to expand as a result of a number of important factors, including the rising prevalence of muscular dystrophy in the region, FDA drug approval, strong healthcare infrastructure supported by supportive government regulations, and medical reimbursement in the region and due to anticipated product launches.

Asia Pacific market is expected to hold the second largest share of global market. On the back of the region's high prevalence of musculoskeletal illnesses and large male population. In India, for example, 51.96% of the population would be male, according to the World Bank. In addition, it is expected that the market will rise due to the ongoing improvement of public healthcare services and strong economic expansion. The pharmaceutical firms in the region are relocating clinical trial operations to new trial areas, which are primarily low- and middle-income countries. Additionally, the region's high frequency of the target condition is anticipated to fuel regional market expansion.

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Global Duchenne Muscular Dystrophy Market Dynamics

Driver

  • Prevalence of duchenne muscular dystrophy is on the rise, and factors that are driving its market growth include increased awareness campaigns about the disorder, the development of mutation-specific therapies, the rise in product pipelines, the introduction of therapies like Exondys51 and Translarna, and the use of corticosteroid-based anti-inflammatory drugs.
  • Other factors driving the growth of the duchenne muscular dystrophy market include the population's potential for rising healthcare costs in developed nations and the accessibility of medical reimbursement in various locations. The long-standing unmet need for the treatment of muscular dystrophy illnesses represents the primary growth opportunity for a number of market competitors. Numerous businesses are now conducting clinical studies to prepare new medications for DMD treatment.

Restraint

  • Global duchenne muscular dystrophy market is anticipated to see significant challenges due to late diagnosis of DMD and decreased seeking rate as a result of prognosis. The fact that different outcome measures are needed at various stages of the disease and that these measures frequently lack sensitivity and objectivity makes it difficult to track how well DMD medications are working right now. For example, the 6 minute walk test, the most used outcome measure in DMD clinical trials, can only be used on ambulant DMD patients (5 years of age) and requires a sizable cohort and a lengthy period of time after treatment to detect a meaningful benefit. A lack of valid outcome measures for these particular age ranges also frequently results in the exclusion of very young children (4 years of age) and non-ambulant patients (12 years of age) from clinical trials. The market for treatments for Duchenne muscular dystrophy is growing as a result of the aforementioned claims.

Speak to one of our ABIRAW analyst for your custom requirements before the purchase of this report

Global Duchenne Muscular Dystrophy Market Competitive Landscape

Global duchenne muscular dystrophy market is competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D.

Top Players in the Global Duchenne Muscular Dystrophy Market

Recent Developments

  • In June 2022, Bristol-Myers Squibb has agreed to acquire Turning Point Therapeutics for $4.1bn in the latest in a series of bolt-on acquisitions by pharmaceutical companies looking to bolster their drug pipelines.
  • In Feb 2022, Recipharm acquires Portuguese CDMO as part of biologics expansion. CDMO GenIbet, specializes in producing biological clinical trial material and other viral vectors, for an undisclosed price.

Global Duchenne Muscular Dystrophy Key Market Trends

  • The introduction of novel pharmaceuticals and treatments, disease-modifying treatments, significant backing from numerous firms for drug research, and support from patient advocacy groups on the regulatory approval process are the main factors driving the global market for duchenne muscular dystrophy.
  • Mutation suppression is anticipated to be one of the most popular treatments for Duchenne muscular dystrophy among the many treatments that are now available. The particular mutation that causes muscular dystrophy is the focus of mutation suppression therapy for duchenne muscular dystrophy. Additionally, nonsense mutation suppression therapy has the potential to help many individuals with duchenne. However, a number of treatments are presently undergoing clinical testing, and a few are almost ready for FDA clearance (FDA).

Global Duchenne Muscular Dystrophy Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected utilizing Primary Exploratory Research backed by the robust Secondary Desk research.

According to our analysis, North America dominated the global market attributed to rising prevalence of muscular dystrophy in the region, FDA drug approval, strong healthcare infrastructure supported by supportive government regulations, and medical reimbursement in the region and due to anticipated product launches. Among these the segment of Exon Skipping Approach held the largest share as the segment has grown due to result of EXONDYS 51 becoming more widely used. Based on distribution channel, the hospital pharmacy segment to grow at faster rate. The Duchenne muscular dystrophy market includes the introduction of novel medications and treatments, substantial funding from numerous companies for drug development, disease-modifying treatments, and assistance from patient advocacy groups for the regulatory approval procedure

Report Metric Details
Market size value in 2021 USD 693.34 million
Market size value in 2028 USD 1533.72 million
Growth Rate more than 11.87%
Base year 2021
Forecast period 2022–2028
Forecast Unit (Value) USD Million
Segments covered
  • Therapy
    • Mutation Suppression, Exon Skipping Approach, Others Therapies
  • Distribution Channel
    • Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Global Duchenne Muscular Dystrophy Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Global Duchenne Muscular Dystrophy Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Global Duchenne Muscular Dystrophy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Duchenne Muscular Dystrophy Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Duchenne Muscular Dystrophy Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Global Duchenne Muscular Dystrophy Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$3,500
BUY NOW GET SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

SPEAK TO AN ANALYST

FAQ's

Global duchenne muscular dystrophy market was valued at USD 693.34 million in 2021, and it is expected to reach a value of USD 1533.72 million by 2028, at a CAGR of more than 11.87% over the forecast period (2022–2028).

Global duchenne muscular dystrophy market is competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Eli Lilly and Company (US)', 'Pfizer Inc. (US)', 'PTC Therapeutics Inc. (US)', 'Janssen Pharmaceuticals Inc. (Belgium)', 'Bristol-Myers Squibb Company (US)', 'Acceleron Pharma Inc. (US)', 'BioMarin Pharmaceutical Inc. (US)', 'Nippon Shokubai Co., Ltd (Japan)', 'Lexicon Pharmaceuticals Inc. (US)', 'Taiho Pharmaceutical Co., Ltd (Japan)'

Prevalence of duchenne muscular dystrophy is on the rise, and factors that are driving its market growth include increased awareness campaigns about the disorder, the development of mutation-specific therapies, the rise in product pipelines, the introduction of therapies like Exondys51 and Translarna, and the use of corticosteroid-based anti-inflammatory drugs.

The introduction of novel pharmaceuticals and treatments, disease-modifying treatments, significant backing from numerous firms for drug research, and support from patient advocacy groups on the regulatory approval process are the main factors driving the global market for duchenne muscular dystrophy.

North America dominated the global duchenne muscular dystrophy market. The market in North America is expected to expand as a result of a number of important factors, including the rising prevalence of muscular dystrophy in the region, FDA drug approval, strong healthcare infrastructure supported by supportive government regulations, and medical reimbursement in the region and due to anticipated product launches.

Speak With Our Analyst

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Duchenne Muscular Dystrophy Market

Product ID: SQSG35I2036

$3,500
BUY NOW GET SAMPLE